论文部分内容阅读
试图消灭Ph~1阳性细胞于慢性期大部分甚至全部慢性粒细胞白血病(简称CGL)病人在作出诊断时,骨髓中可能有残留的Ph~1阴性(因而也许是正常的)造血干细胞存活。极少数病人诊断时骨髓Ph~1阳性,用马利兰治疗后转为阴性,而这些病人的生存期意外地长。基于以上认识,人们试图抑制Ph~1阳性细胞群,希望能够让Ph~1阴性的造血机能重新出现。 1979年,纽约S1oan-Kettering研究所发表了L-5方案初步结果报告。37例初诊的CGL患者,首先进行脾脏放射治疗,再行脾切除术,然后接受多种通常用于急性粒细胞白血病
Attempting to Eliminate Ph ~ 1-positive Cells In the chronic phase Most, if not all, patients with chronic myeloid leukemia (CGL) may have residual Ph-1 negative (and perhaps normal) hematopoietic stem cell survival in the bone marrow at diagnosis. Very few patients diagnosed with bone marrow Ph ~ 1 positive, with the treatment of Maryland turned negative, and the survival of these patients unexpectedly long. Based on the above understanding, people try to inhibit Ph ~ 1-positive cell population, hoping to make Ph ~ 1-negative hematopoietic function re-emerged. In 1979, New York, S1oan-Kettering Institute published preliminary results of the L-5 program. 37 cases of newly diagnosed CGL patients, the first spleen radiation therapy, and then splenectomy, and then receive a variety of commonly used for acute myeloid leukemia